BR112014017882A2 - formulações estabilizadas contendo anticorpos anti-ang-2 - Google Patents

formulações estabilizadas contendo anticorpos anti-ang-2

Info

Publication number
BR112014017882A2
BR112014017882A2 BR112014017882A BR112014017882A BR112014017882A2 BR 112014017882 A2 BR112014017882 A2 BR 112014017882A2 BR 112014017882 A BR112014017882 A BR 112014017882A BR 112014017882 A BR112014017882 A BR 112014017882A BR 112014017882 A2 BR112014017882 A2 BR 112014017882A2
Authority
BR
Brazil
Prior art keywords
ang
antibodies
antibody
containing anti
formulations containing
Prior art date
Application number
BR112014017882A
Other languages
English (en)
Inventor
Dix Daniel
Walsh Scott
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47633582&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014017882(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112014017882A2 publication Critical patent/BR112014017882A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

resumo patente de invenção: "formulações estabilizadas contendo anticorpos anti-ang-2". a presente revelação proporciona formulações farmacêuticas que compreendem um anticorpo que se liga especificamente a angiopoietina 2 (ang-2). as formulações podem conter, além de um anticorpo anti-ang-2, pelo menos um aminoácido, pelo menos um açúcar ou pelo menos um surfactante não iônico. as formulações farmacêuticas da presente invenção apresentam um grau substancial de estabilidade do anticorpo após armazenagem por vários meses e após serem submetidas ao estresse térmico e a outros estresses físicos. 21846557v1 1/1 21846557v1
BR112014017882A 2012-01-23 2013-01-22 formulações estabilizadas contendo anticorpos anti-ang-2 BR112014017882A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261589427P 2012-01-23 2012-01-23
PCT/US2013/022473 WO2013112438A1 (en) 2012-01-23 2013-01-22 Stabilized formulations containing anti-ang2 antibodies

Publications (1)

Publication Number Publication Date
BR112014017882A2 true BR112014017882A2 (pt) 2017-06-27

Family

ID=47633582

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017882A BR112014017882A2 (pt) 2012-01-23 2013-01-22 formulações estabilizadas contendo anticorpos anti-ang-2

Country Status (23)

Country Link
US (1) US9402898B2 (pt)
EP (1) EP2807190B1 (pt)
JP (1) JP6113756B2 (pt)
KR (1) KR102063028B1 (pt)
CN (1) CN104169299B (pt)
AR (1) AR089787A1 (pt)
AU (1) AU2013212587B2 (pt)
BR (1) BR112014017882A2 (pt)
CA (1) CA2861062A1 (pt)
CL (1) CL2014001930A1 (pt)
EA (1) EA033387B1 (pt)
HK (1) HK1204631A1 (pt)
IL (1) IL233482B (pt)
JO (1) JO3533B1 (pt)
MA (1) MA35904B1 (pt)
MX (1) MX357393B (pt)
MY (1) MY164611A (pt)
NZ (1) NZ627859A (pt)
PH (1) PH12014501628B1 (pt)
SG (1) SG11201403792TA (pt)
TW (1) TWI615149B (pt)
UY (1) UY34587A (pt)
WO (1) WO2013112438A1 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201403792TA (en) 2012-01-23 2014-10-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
EP3149034B1 (en) * 2014-05-30 2022-07-13 New England Biolabs, Inc. Deglycosylation reagents and methods
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016061551A1 (en) 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
AU2016368099C1 (en) 2015-12-07 2023-10-12 Merck Patent Gmbh Aqueous Pharmaceutical Formulation Comprising anti-PD-L1 Antibody Avelumab
DK3479819T3 (da) * 2016-06-30 2024-04-15 Celltrion Inc Stabilt væskeformigt farmaceutisk præparat
FR3054444A1 (fr) * 2016-07-29 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnf alpha
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
WO2018122053A1 (en) * 2016-12-29 2018-07-05 F. Hoffmann-La Roche Ag Anti-angiopoietin-2 antibody formulation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
KR20200004366A (ko) 2017-05-06 2020-01-13 리제너론 파아마슈티컬스, 인크. Aplnr 길항제 및 vegf 저해제를 이용한, 안 장애의 치료 방법
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
EP3727629A1 (en) 2017-12-22 2020-10-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
US20190225689A1 (en) * 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
CN111655722A (zh) 2018-01-31 2020-09-11 瑞泽恩制药公司 用于表征药物产品杂质的***和方法
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
BR112020013426A2 (pt) 2018-02-28 2020-12-01 Regeneron Pharmaceuticals, Inc. métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células
CN111868085A (zh) 2018-03-19 2020-10-30 瑞泽恩制药公司 微芯片毛细管电泳测定法及试剂
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CN112218877A (zh) 2018-08-27 2021-01-12 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN112601963A (zh) 2018-08-30 2021-04-02 瑞泽恩制药公司 用于表征蛋白质复合物的方法
CA3116732A1 (en) 2019-01-16 2020-07-23 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
CN113728004A (zh) * 2019-02-25 2021-11-30 药物抗体公司 抗Ang2抗体及其用途
JP7420827B2 (ja) * 2019-03-08 2024-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ－３６ｒ抗体製剤
EP3969908A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
MX2022003438A (es) 2019-09-24 2022-04-19 Regeneron Pharma Sistemas y metodos para uso y regeneracion de cromatografia.
KR20220104797A (ko) 2019-11-25 2022-07-26 리제너론 파마슈티칼스 인코포레이티드 비수성 에멀전을 이용한 지속 방출 제형
KR102544013B1 (ko) 2020-01-21 2023-06-19 리제너론 파마슈티칼스 인코포레이티드 당질화된 단백질의 전기영동을 위한 탈당질화 방법
WO2022010988A1 (en) * 2020-07-08 2022-01-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ctla-4 antibodies
EP4204578A1 (en) 2020-08-31 2023-07-05 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
KR20230113280A (ko) 2020-11-25 2023-07-28 리제너론 파마슈티칼스 인코포레이티드 비수성 멤브레인 유화법을 사용한 지속 방출 제형
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
AU2022230987A1 (en) 2021-03-03 2023-08-31 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
BR112023018665A2 (pt) 2021-03-26 2023-10-03 Regeneron Pharma Métodos e sistemas para desenvolvimento de protocolos de mistura
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
WO2023059800A2 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
AU2022359898A1 (en) 2021-10-07 2024-03-21 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
WO2023177836A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
AU670793B2 (en) 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2324115C (en) 1998-03-17 2008-12-23 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
AU1344102A (en) 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
JP4583762B2 (ja) 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
ZA200506159B (en) * 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
MX2007004247A (es) * 2004-10-19 2007-06-12 Amgen Inc Agentes de aglutinacion especifica a angiopoyetina-2.
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005319382B2 (en) 2004-12-21 2011-04-07 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
LT2586459T (lt) 2005-03-25 2017-09-25 Regeneron Pharmaceuticals, Inc. Vegf antagonisto kompozicijos
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
LT2944306T (lt) 2006-06-16 2021-02-25 Regeneron Pharmaceuticals, Inc. Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu
RU2509085C2 (ru) * 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2403874A1 (en) 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
IT1396433B1 (it) * 2009-11-16 2012-11-23 Rolic Invest Sarl Impianto eolico per la generazione di energia elettrica e metodo per realizzare un pilone del suddetto impianto eolico.
WO2011061712A1 (en) 2009-11-20 2011-05-26 Biocon Limited Formulations of antibody
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
SG11201403792TA (en) 2012-01-23 2014-10-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
EA033387B1 (ru) 2019-10-31
PH12014501628A1 (en) 2014-10-13
AR089787A1 (es) 2014-09-17
KR102063028B1 (ko) 2020-01-07
NZ627859A (en) 2015-09-25
TWI615149B (zh) 2018-02-21
EP2807190A1 (en) 2014-12-03
US20130186797A1 (en) 2013-07-25
JP2015505539A (ja) 2015-02-23
KR20150000873A (ko) 2015-01-05
MX2014008874A (es) 2014-09-01
US9402898B2 (en) 2016-08-02
IL233482B (en) 2019-06-30
IL233482A0 (en) 2014-08-31
EP2807190B1 (en) 2018-12-26
AU2013212587B2 (en) 2017-07-20
EA201491414A1 (ru) 2014-12-30
CN104169299B (zh) 2018-06-05
JP6113756B2 (ja) 2017-04-12
MY164611A (en) 2018-01-30
WO2013112438A1 (en) 2013-08-01
MX357393B (es) 2018-07-06
CA2861062A1 (en) 2013-08-01
TW201343177A (zh) 2013-11-01
HK1204631A1 (en) 2015-11-27
UY34587A (es) 2013-07-31
PH12014501628B1 (en) 2014-10-13
JO3533B1 (ar) 2020-07-05
CN104169299A (zh) 2014-11-26
SG11201403792TA (en) 2014-10-30
MA35904B1 (fr) 2014-12-01
CL2014001930A1 (es) 2014-10-03
AU2013212587A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
BR112014017882A2 (pt) formulações estabilizadas contendo anticorpos anti-ang-2
BR112013008366A2 (pt) formulações estabilizadas contendo anticorpos de receptor de anti-interleucina-4 (il-4r)
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
BR112014001712A2 (pt) formulações estabilizadas contendo anticorpos anti-pcsk9
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
BR112013002764A8 (pt) formulações esatabilizadas contendo anticorpos anti-ngf
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
BR112014028997A2 (pt) formulações estabilizadas contendo anticorpos anti-dll4
BR112018002196A2 (pt) formulação anti-ifnar1 estável
BR112014021325A2 (pt) Formulação farmacêutica líquida e formulação liofilizada
BRPI0909044B8 (pt) anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
EA201391613A1 (ru) КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
BR112015030229A2 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
BR112017002183A2 (pt) conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero
BRPI0919236A8 (pt) Terapêutica e vacinas de combinação de gas
BR112013025294A2 (pt) moléculas de ligação biespecífica ligando a dll4 e ang2
BR112013000840A2 (pt) método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial.
UY33652A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)
BR112014015605A2 (pt) método de reconstituição para formulações de proteína seca de alta concentração
TH175929A (th) สูตรตำรับของแอนติบอดี้ (Antibody Formulation)
TH151570A (th) สูตรผสมคงตัวที่มีแอนติ-ang2 แอนติบอดี
TH154849A (th) สูตรตำรับที่บรรจุแอนติบอดีต้าน-dll4 ที่ถูกเพิ่มความคงตัว

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements